NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
SJG-136 in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00103220
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal CancerMetastatic Cancer
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00103298
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
Phase 2
Completed
- Conditions
- Diffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Gastric CancerStage III Gastric CancerStage IV Gastric Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00103324
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
Phase 2
Completed
- Conditions
- Stage I Prostate CancerStage IIA Prostate CancerStage III Prostate CancerStage IIB Prostate CancerRecurrent Prostate Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 49
- Registration Number
- NCT00103194
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Cilengitide in Treating Patients With Metastatic Prostate Cancer
Phase 2
Completed
- Conditions
- Recurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 106
- Registration Number
- NCT00103337
- Locations
- 🇺🇸
University of Michigan University Hospital, Ann Arbor, Michigan, United States
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Recurrent Colon CancerStage IIIA Rectal CancerStage IIIB Rectal CancerStage IIIC Rectal CancerStage IVA Colon CancerRecurrent Rectal CancerStage IIIC Colon CancerStage IIIA Colon CancerStage IIIB Colon CancerStage IVA Rectal Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00103311
- Locations
- 🇺🇸
University of Southern California, Norris, Los Angeles, California, United States
Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2020-06-12
- Target Recruit Count
- 272
- Registration Number
- NCT00103402
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Temple University, Philadelphia, Pennsylvania, United States
🇺🇸Northwestern U. Feinberg School of Medicine, Chicago, Illinois, United States
Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes
Terminated
- Conditions
- AnemiasHemoglobinopathiesHemolysisIron Deficiency and Overload
- First Posted Date
- 2005-01-26
- Last Posted Date
- 2018-02-14
- Target Recruit Count
- 334
- Registration Number
- NCT00102245
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Basal Cell Carcinoma of the LipRecurrent Colon CancerRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityRecurrent Lymphoepithelioma of the NasopharynxRecurrent Lymphoepithelioma of the OropharynxRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Interventions
- Biological: cetuximabBiological: bevacizumabOther: laboratory biomarker analysis
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT00101348
- Locations
- 🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1
Terminated
- Conditions
- Angioimmunoblastic T-cell LymphomaChildhood Burkitt LymphomaChildhood Immunoblastic Large Cell LymphomaHepatosplenic T-cell LymphomaIntraocular LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Childhood Acute Lymphoblastic LeukemiaChildhood Nasal Type Extranodal NK/T-cell LymphomaRecurrent Childhood Anaplastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00101205
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States